ORCHPHARMA.NSORCHPHARMA.NSNSE
Loading
EBITDA Margin Over TimeContracting
Percentile Rank13
3Y CAGR-27.3%
5Y CAGR-10.6%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-27.3%/yr
vs -10.4%/yr prior
5Y CAGR
-10.6%/yr
Recent deceleration
Acceleration
-16.9pp
Decelerating
Percentile
P13
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM8.24%-47.5%
202515.69%-9.4%
202417.33%-19.3%
202321.47%+93.3%
202211.10%-23.1%
202114.44%+33.4%
202010.83%-67.5%
201933.28%+531.3%
20185.27%+175.0%
2017-7.03%-